Landscapes / Targets
HER3
19 drugs act on HER3, in 121 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs19
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Monoclonal antibody |
Approved | 31 Dec 2026Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 31 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion and 2 more | ||||
| Open drug page | |||||
EGFR/HER3 bispecific antibody-drug conjugate |
Sichuan Baili (Biokin, SystImmune) +1 · Public BMY |
Phase 3 | Nov 2026soonPhase 3 trial completes | ||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, Solid Tumor and 44 more | ||||
| Open drug page | |||||
— |
Phase 3 | Nov 2026soonPhase 2 trial completes | |||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer and 6 more | ||||
| Open drug page | |||||
— |
Phase 3 | Nov 2026soonPhase 2 trial completes | |||
| Next date | Nov 2026 · Phase 2 trial completes | ||||
| Also tested for | Non Small Cell Lung Cancer, Breast Cancer and 8 more | ||||
| Open drug page | |||||
HER3-targeted antibody-drug conjugate |
Hengrui · Public 600276.SS |
Phase 3 | Dec 2026Phase 3 trial completes | ||
| Next date | Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Non-small Cell Lung Cancer, Advanced Solid Tumors and 1 more | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Jun 2027Phase 2 trial completes | |||
| Next date | 30 Jun 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Non-small Cell Lung Cancer, Advanced Malignant Solid Tumor and 5 more | ||||
| Open drug page | |||||
HER3-targeted antibody-drug conjugate |
Daiichi Sankyo +1 · Public MRK |
Phase 3 | 9 May 2028Phase 1/2 trial completes | ||
| Next date | 9 May 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Non-Small Cell Lung Cancer (NSCLC), Breast Cancer and 30 more | ||||
| Open drug page | |||||
— |
Innovent · Public 1801.HK |
Phase 1/2 | 30 Jun 2027Phase 1/2 trial completes | ||
| Next date | 30 Jun 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Unresectable, Locally Advanced or Metastatic Solid Tumors and 1 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | Jul 2027Phase 1/2 trial completes | |||
| Next date | Jul 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Melanoma (Skin), Non Small Cell Lung Cancer and 1 more | ||||
| Open drug page | |||||
— |
Junshi Biosciences · Public 1877.HK |
Phase 2 | 30 Nov 2027Phase 2 trial completes | ||
| Next date | 30 Nov 2027 · Phase 2 trial completes | ||||
| Also tested for | Non-squamous Non-small Cell Lung Cancer, Advanced Lung Cancer and 3 more | ||||
| Open drug page | |||||
— |
CSPC · Public 1093.HK |
Phase 2 | 30 Nov 2027Phase 2 trial completes | ||
| Next date | 30 Nov 2027 · Phase 2 trial completes | ||||
| Also tested for | Advanced Solid Tumor, Advanced Breast Cancer | ||||
| Open drug page | |||||
— |
Phase 1/2 | 1 Dec 2027Phase 1/2 trial completes | |||
| Next date | 1 Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma and 9 more | ||||
| Open drug page | |||||
— |
Phase 1/2 | 30 Dec 2027Phase 1/2 trial completes | |||
| Next date | 30 Dec 2027 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumor | ||||
| Open drug page | |||||
— |
Phase 1/2 | Apr 2028Phase 1/2 trial completes | |||
| Next date | Apr 2028 · Phase 1/2 trial completes | ||||
| Also tested for | Advanced Solid Tumors Cancer | ||||
| Open drug page | |||||
— |
Phase 2 | — | |||
| Also tested for | Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction | ||||
| Open drug page | |||||
SIBP-03not checked |
— |
Phase 2 | — | ||
| Also tested for | Head and Neck Squamous Cell Carcinoma | ||||
| Open drug page | |||||
— |
Huadong Medicine · Public 000963.SZ |
Phase 1 | 15 Apr 2027Phase 1 trial completes | ||
| Next date | 15 Apr 2027 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumors | ||||
| Open drug page | |||||
— |
Phase 1 | 1 Jul 2028Phase 1 trial completes | |||
| Next date | 1 Jul 2028 · Phase 1 trial completes | ||||
| Also tested for | Advanced Solid Tumor Malignancies | ||||
| Open drug page | |||||
— |
Phase 1 | — | |||
| Also tested for | Advanced Solid Tumor | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 18 of 19 drugs. The other 1 is marked “not checked” in the list. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026